Matt, Author at European Medical Journal - Page 34 of 212

Congress Interview Professor John B.A.G. Haanen

ESMO Congress Interview: Professor John B.A.G. Haanen

You have an impressive scientific background, completing a scientific PhD in immunohaematology in addition to your clinical training…

EMJ Oncology 8.1 2020 Feature Image

Long-term Survival Following Photodynamic Therapy for Glioma Depending on MGMT

The gross total resection of a glial tumour is the aim of complex treatment and gives greater efficiency of the subsequent treatment stages, defining patients’ longevity…

Interview: Dr Vinay Prasad

Interview: Dr Vinay Prasad

You have an impressive background in science communication within the medical field, not only working with patients as a haematologist…

EMJ Oncology 8.1 2020 Feature Image

Long-Term Follow-Up of Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Report From the Spanish Lymphoma Oncology Group

Nodular lymphocytic predominance Hodgkin lymphoma (NLPHL) is a very uncommon subtype of Hodgkin lymphoma (HL), representing approximately 5% of all HL cases, with an incidence of 0.3/100,000 cases per year and with unique characteristics that distinguish it from classic HL…

EMJ Oncology 8.1 2020 Feature Image

Evolution of Adjuvant Therapy in Radically Resected Carcinoma Gallbladder Over a Decade: A Real-World Experience from a Regional Cancer Centre

Because of the rarity and high mortality of gallbladder cancer (GBC), the best adjuvant modality of radically resected GBC is not well established…

EMJ Oncology 8.1 2020 Feature Image

Safety of Fertility Treatments in Breast Cancer Survivors

Quality of life for cancer survivors has become a priority in cancer care and research. Almost 50% of the young patients who have survived breast cancer (BC) have expressed their desire to become pregnant…

EMJ Oncology 8.1 2020 Feature Image

The Importance of Molecular Testing in the Treatment of Cholangiocarcinoma

Cholangiocarcinomas (CCA) belong to the constellation of biliary tract cancers (BTC), along with gallbladder carcinomas and ampullary carcinomas…

PEAR Study: UK Experience of the Management of Pregnancy-Associated brEast cAnceR: A National Retrospective Review of Practice

Breast cancer is the leading cause of death in females aged 35–54 years and 15% of breast cancers first present in females of reproductive age…

race against time

Breast cancer (BC), which is the most prevalent malignancy in women worldwide, is a heterogeneous disease, in which human epidermal growth…

Association of Tumour Location and Recurrence in Patients with Non-Muscle Invasive Bladder Cancer

Risk stratification and prognosis estimation is important in patients with non-muscle invasive bladder cancer (NMIBC). NMIBC has a high probability…